Genome British Columbia Invests in Acuva Technologies, Canadian UV-LED Water Disinfection Company Empowering Safe Drinking Water Globally

Safe water supply and adequate sanitation to protect health are basic human necessities. However, the World Health Organization (2017) reports that 3.4 million people, mostly children, die from water-related diseases each year. Access to safe drinking water contributes to improved health, reduced risk of waterborne diseases. Acuva's compact, energy efficient UV-LED water treatment technology offers huge potential to address this global issue.

Through its Strike Platform of customizable UV-LED drinking water disinfection modules, Acuva is helping make safe drinking water more accessible through its partnerships with global Original Equipment Manufacturers (OEMs) of water, ice and beverage dispensing appliances. Advanced applications of this technology also include integration into lab water equipment.

"Our province still has communities where safe drinking water is not consistently available," says Dr. Tony Brooks, Chief Financial Office and Vice President, Entrepreneurship and Commercialization. "Genome BC not only seeks to better the lives of British Columbians through this investment, but also to support global efforts for the millions of people around the world who still struggle on a daily basis for access to clean water."

Genome BC has invested $1 million in Acuva Technologies through its Industry Innovation (I²) program. The I² Fund provides commercialization support for companies developing innovative life science technologies that address biological challenges in key economic sectors in BC: Agriculture, Energy and Mining, Environment, Fisheries and Aquaculture, Forestry, and Human Health. The I² Fund also supports digital health and other technologies that further move precision medicine into clinical practice. I² funding is repayable and is allocated to promising technologies (products, processes or services) at the early stages of commercial development. The Fund aims to provide risk capital that is concurrently matched by other public or private funding sources.

Media Inquiries
Interview opportunities with Manoj Singh, President & CEO of Acuva Technologies; and Fariborz Taghipour, CTO of Acuva Technologies are available upon request. For more information, contact Romina Puno at media@acuvatech.com or +1.778.222.1757.